Alagille syndrome is a genetic disorder, in which a person have fewer bile ducts than normal in liver. Alagille syndrome can be passed from parent to child or can happen naturally. Alagille syndrome not only affects the liver, it can also cause skin, heart, facial, kidney, and eye abnormalities. While there is no known cure for Alagille syndrome, there are treatments that can help control the symptoms. Possible treatments may include medications such as Ursodeoxycholic acid, Cholestyramine, and Rifampicin that increases the flow of bile and careful management of diet to minimize nutrition and vitamin related problems. In severe cases, a liver transplant may be necessary.
Several pharmaceutical companies manufacture drugs to control the symptoms such as Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals and others. There are two drugs under the clinical trials that have the potential to treat Alagille syndrome more effectively than other medications. The two drugs are Odevixibat and Maralixibat. Furthermore, the U.S. FDA is providing support to the manufacturers by giving orphan drug designation or breakthrough designation to the new drugs.
Market Dynamics
Key players in the market are gaining huge amount of funding for the research of Alagille syndrome treatment for new drugs, which is expected to boost the Alagille syndrome treatment market growth over the forecast period. For instance, the Alagille Syndrome Alliance, an international nonprofit started in 1993, offers funding for Research Grant Program for ALGS and Science for research and development of novel therapies for Alagille syndrome treatment and encourage ALGS research in new investigators. The grant offers US$ 30,000 for each year for development of novel drug compounds.
However, lack of novel therapies is expected to restrain the Alagille syndrome treatment market growth. For instance, according to the National Organization for Rare Disorders, Alagille syndrome is caused by mutations in one of two genes – the JAG1 gene or the NOTCH2 gene. Mutations of the JAG1 gene have been identified in over 88% of cases of Alagille syndrome. Mutations in the NOTCH2 gene account for less than 1% of cases. These mutations are inherited in an autosomal dominant pattern, and finding cure for genetic disorders require extensive R&D, which is often not achieved.
Key features of the study:
- This report provides in-depth analysis of the global Alagille syndrome treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global Alagille syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., and Mirum Pharmaceuticals.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global Alagille syndrome treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Alagille syndrome treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Alagille Syndrome Treatment Market, By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- Global Alagille Syndrome Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Alagille Syndrome Treatment Market, By Region:
- North America
- By Country:
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi S.A.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.
